Immatics NV
IMTX
Company Profile
Business description
Immatics NV is a clinical-stage biotechnology company engaged in the research and development of T-cell redirecting immunotherapies for the treatment of cancer patients. The company earns revenue through strategic collaboration agreements with third-party pharmaceutical and biotechnology companies. The company derives its maximum revenue from United States.
Contact
Paul-Ehrlich-Strasse 15
TubingenBW72076
DEUT: +49 707153970
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
407
Stocks News & Analysis
stocks
The best AI stocks to buy now
Artificial intelligence stocks maintain their allure, thanks to industry momentum and appealing valuations.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,854.80 | 31.60 | 0.36% |
| CAC 40 | 7,729.69 | 39.52 | -0.51% |
| DAX 40 | 24,806.97 | 297.39 | -1.18% |
| Dow JONES (US) | 51,231.64 | 51.77 | 0.10% |
| FTSE 100 | 10,441.60 | 16.90 | -0.16% |
| HKSE | 23,785.79 | 344.71 | -1.43% |
| NASDAQ | 27,193.34 | 345.35 | -1.25% |
| Nikkei 225 | 69,042.11 | 993.60 | -1.42% |
| NZX 50 Index | 13,648.16 | 43.69 | -0.32% |
| S&P 500 | 7,765.36 | 36.41 | -0.47% |
| S&P/ASX 200 | 8,693.60 | 32.70 | 0.38% |
| SSE Composite Index | 3,811.90 | 30.29 | -0.79% |